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Paradox of vaccination in 
cervical cancer and screening
The development of human papillomavirus 
(HPV) vaccines and their potential for reducing 
cervical cancer incidence and mortality are 
generally considered important steps to 
improve population health worldwide. For 
countries without well performing cervical 
cancer screening programmes and lack of 
treatment options the current epidemiological 
and economic models seem applicable.
However, the assumptions underlying 
published economic evaluations in countries 
with high coverage, well functioning screening 
programmes, such as that by Jit et al from 
the United Kingdom,1  neglect an important 
limitation to the validity of their models. There 
is a non-negligible risk that a high HPV vaccine 
coverage in adolescents will lead to a decrease 
in screening uptake in later years because 
vaccinated women will see themselves as no 
longer at risk and will consequently avoid the 
unpleasant screening procedure.
As about 30% of cervical cancers are not 
caused by the current HPV vaccines against HPV 
types 16 and 18, there is a real risk of increased 
cervical cancer incidence and mortality 
in women who do not take up screening, 
counterbalancing the positive effects of the HPV 
vaccination. This is fuelled by health promotion 
material from manufacturers, cancer councils, 
and Cancer Research UK, all of which market the 
HPV vaccines as “cervical cancer vaccines.” This 
is reflected in the general media and even in 
some leading scientific journals.2-5 
Research investigating the potential impact 
of the HPV vaccines on screening uptake is 
urgently needed to establish the extent of this 
paradoxical effect on cervical cancer incidence 
and mortality and to improve epidemiological 
and economic models to guide future policies 
for cervical cancer prevention.
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glimpse into the black box of 
HPV vaccination
We welcome an opportunity to get a glimpse 
into the black box underlying the recent 
decisions about human papillomavirus (HPV) 
vaccination.1  We would like to reflect on the 
assumptions made. GlaxoSmithKline claims 
that Cervarix will provide protection longer, 
which would favour Cervarix. The paper by Jit 
et al does not reflect this (which is probably 
appropriate, since these claims are disputed).
The paper’s assumption that those receiving 
fewer than three doses received no protection 
is conservative: two doses do provide some 
protection. Evaluation of the programme will 
allow us to assess this further.
Vaccination may allow an increased 
screening interval (with or without HPV testing). 
The paper does not seem to model the savings 
that might result.2 
The paper’s estimate of the cost of treating 
genital warts (£216 (€275; $430) per 
successful treatment) is lower than estimates 
elsewhere.3  Given this, the high and increasing 
incidence of genital warts,3  4  the need for 
repeated treatments, and the psychosocial 
costs of genital warts, we wonder whether the 
benefits of quadrivalent Gardasil have been 
underestimated.
It is not clear whether discounting has 
taken into account the earlier benefits of wart 
prevention, which would tend to tip the balance 
more in favour of Gardasil.
HPV causes other cancers. Some data 
indicate that anal cancer rates in men who have 
sex with men might exceed cervical cancer rates 
in women; and that more anal than cervical 
cancers might be prevented by vaccination.5  
Consideration of other cancers would not only 
favour introducing the vaccine but might also tip 
the balance towards vaccinating boys as well as 
girls, thus mitigating equity issues and avoiding 
the impression that sexual health is only an 
issue for girls. Furthermore, if vaccine uptake is 
low, then vaccinating boys will be necessary to 
achieve herd immunity.
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peripHeral intravenous catHeters
It’s who looks after the 
catheters that counts
Maki asserts that the incidence of intravenous 
catheter complications is greatly reduced when 
highly experienced nurses insert catheters.1  
The single reference provided to support 
this statement makes interesting reading.2  
This randomised controlled trial compares 
complications in two main groups of patients: 
those who are cannulated by house doctors 
and followed up by ward staff and those who 
are under the care of the intravenous therapy 
team. The latter group is checked daily for 
complications by experienced nurses, but their 
cannulas are inserted by doctors and nurses 
in similar numbers. The intravenous therapy 
nurses do a sterling job it seems between 9 am 
and 5 pm, but in time honoured tradition it is 
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the house doctors who perform all intravenous 
cannulation between 5 pm and 9 am and at 
weekends.
The complication rates for patients who are 
subsequently followed up by the intravenous 
therapy nurses were slightly higher for the 
nurse inserted cannulas (9.3%) than the doctor 
inserted cannulas (6%).2  The three episodes 
of line related sepsis in the house doctor group 
(not undergoing routine daily review) seem to be 
related to duration in situ rather than any other 
factor. One of these three cannulas was actually 
inserted by paramedics rather than the house 
doctors.
The paper clearly states that the maintenance 
and timely removal of intravenous catheters 
is more important than the specific personnel 
inserting the catheters in determining the 
occurrence of complications.
It is frustrating to see an editorial make a 
rather sweeping statement that is not supported 
by the relevant citation.
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professional conduct
Confidence in child  
protection practice
see features pp 258, 262 
The Royal College of Paediatrics and Child 
Health welcomes the guidance for expert 
witnesses produced by the General Medical 
Council.1 The key points describe the rules 
and legislation that should be familiar to all 
paediatricians who attend court. It closely 
echoes the important statement from the 
Department of Health and the Department 
of Children, Schools, and Families.2 This 
should protect the public and, importantly, 
paediatricians who have felt vulnerable when 
giving evidence as expert or professional 
witnesses. Paediatricians are particularly 
involved in family courts, and the GMC guidance 
should be read alongside the Handbook for 
Expert Witnesses in Children Act Cases.3
However, the GMC must itself look to its own 
procedures.
Gornall describes the GMC’s withdrawal of 
the longstanding case, partway through, against 
three paediatricians4 (p 258). We are pleased 
with this decision but remain concerned about 
the unnecessary distress caused to doctors by 
unacceptable delays and the issues around 
potentially conflicted expert witnesses. We 
know the GMC recognises these problems, and 
the recent guidance describes the responsibility 
of experts to declare potential conflicts and the 
courts to decide on appropriate action.
Dyer notes that the Crown Prosecution 
Service’s review of “secret” case files held 
by Dr David Southall found no evidence that 
any information was kept from the defence5 (p 
263). This is a welcome and important finding 
and should help to restore the confidence of 
the public in criminal prosecution processes 
as well as the confidence of paediatricians 
who work in difficult circumstances. We know 
that the management of case files and proper 
communication are important parts of child 
protection processes as described by Lord 
Laming in the Victoria Climbie inquiry.
Paediatricians contribute to the protection 
of children by following clearly laid out 
procedures detailed in the government’s 
document Working Together to Safeguard 
Children,6 and they must feel safe from 
unnecessary referral to the GMC or from 
protracted procedures. We hope this guidance 
will help to achieve this and the Royal College 
of Paediatrics and Child Health continues 
to have discussions with the GMC about its 
processes.
Patricia Hamilton president, officer for child protection
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You cannot be serious, says 
gMC to observation article
In an uncharacteristically dyspeptic column, 
Hawkes castigates the General Medical Council 
over several unrelated issues.1  Donning his 
suit of rusty armour and unsheathing the sword 
of truth and justice, he sallies forth to fight 
the battles of yesteryear without fear, favour, 
or much forethought. His points on the end 
of the exemption from the annual retention 
fee for doctors over the age of 65 cannot go 
unchallenged.
As an Aberdonian, I have an ingrained 
interest in matters fiscal. But even I have 
difficulty in accepting that the current fee of 
£390 is an “excessive” sum for a licence to 
practise medicine in this country. The clear 
advice from leading counsel was, and remains, 
that age related exemption from the annual 
retention fee is unlawful under the relevant 
statutory employment regulations. The council 
had no choice but to regularise the position 
as quickly as practicable. It would have been 
preferable to integrate this change for doctors 
over the age of 65 with the introduction of 
licences to practise towards the end of 2009. 
However, as the current arrangements are 
unlawful, this option was not open to us.
Hawkes has, I fear, misread the relevant 
regulation 19(1)(c), which must be read in 
conjunction with regulation 3. Regulation 
19(1)(c) does not say that we cannot 
withdraw or vary the terms on which a 
qualification is held. Rather, it says that we 
cannot discriminate (on grounds of age) by 
withdrawing or varying the terms on which a 
qualification is held. The regulations are not 
about discrimination against elderly people, 
they are about discrimination on the basis 
of age.
The argument about national emergencies 
has been addressed by recent changes which 
empower the registrar of the GMC to grant 
temporary registration, without any fee, to 
individuals with regard to emergencies involving 
loss of human life or human illness.
I understand the Victor Meldrew view that 
standards have slipped, are continuing to slip, 
and that the GMC needs to do something. As 
ever, the truth is more complicated and less 
worrying—even if, along with Victor, you simply 
don’t believe it.
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